Anjemo K, van Rijn M, Verkerk PH, Burgerhof JG, Heiner-Fokkema MR, van Spronsen FJ. PKU: high plasma phenylalanine concentrations are associated with increased prevalence of mood swings. Mol Genet Metab. 2011;104(3):231-4.
Camacho F, Mazuecos J. Oral and topical L-phenylalanine, clobetasol propionate, and UVA/sunlight--a new study for the treatment of vitiligo. J Drugs Dermatol. 2002;1(2):127-31.
Castro IP, Borges JM, Chagas HA, Tiburcio J, Starling AL, Aguiar MJ. Relatinships between phenylalanine levels, intelligence and socioeconomic status of patients with phenylketonuria. J Pediatr. 2012;88(4):353-6.
Dietary Guidelines for Americans 2005. Rockville, MD : US Dept of Health and Human Services and US Dept of Agriculture; 2005.
Dillon EL, Sheffield-Moore M, Paddon-Jones D, Gilkison C, et al. Amino acid supplementation increases lean body mass, basal muscle protein synthesis, and insulin-like growth factor-I expression in older women. J Clin Endocrinol Metab. 2009 May;94(5):1630-7. Epub ahead of print.
Kliegman R. Nelson Textbook of Pediatrics. 19th ed. Philadelphia, PA: Elsevier Saunders; 2011.
Lotti T, Buggiani G, Troiano M, Assad GB, Delescluse J, De Giorgi V, Hercogova J. Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. Dermatol Ther. 2008 Jul;21 Suppl 1:S20-6.
MacLeod EL, Gleason ST, van Calcar SC, Ney DM. Reassessment of phenylalanine tolerance in adults with phenylketonuria is needed as body mass changes. Mol Genet Metab. 2009;98(4):331-7.
Poewe W. Treatments for Parkinson disease--past achievements and current clinical needs. Neurology. 2009 Feb 17;72(7 Suppl):S65-73.
Reuss S, Weiss C, Bayerl C. Phenylalanine and UVA for Vitiligo patients: probability of an effective treatment. Med Hypotheses. 2006;67(1):199-200.
Russell AL, McCarty MF. DL-phenylalanine markedly potentiates opiate analgesia - an example of nutrient/pharmaceutical up-regulation of the endogenous analgesia system. Med Hypotheses. 2000;55(4):283-8.
Sharman R, Sullivan K, Young RM, McGill J. Depressive symptoms in adolescents with early and continuously treated phenylketonuria; associations with phenylalanine and tyrosine levels. Gene. 2012;504(2):288-91.
Szczurko O, Boon HS. A systematic review of natural health product treatment for vitiligo. BMC Dermatol. 2008 May 22;8:2. Review.
Viau KS, Wengreen HJ, Ernst SL, Cantor NL, Furtado LV, Longo N. Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria. J Inherit Metab Dis. 2011;34(4):963-71.
Vockley J, Andersson HC, Antshel KM, et al. Phenlalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med. 2014;16(2):188-200.
Wissman P, Geisler S, Leblhuber F, Fuchs D. Immune activation in patients with Alzheimer's disease is assocaitd with high serum phenylalanine concentrations. J Neurol Sci. 2013;329 (1-2):29-33.